PT2266544T - Método para introdução de substâncias terapêuticas em células - Google Patents
Método para introdução de substâncias terapêuticas em célulasInfo
- Publication number
- PT2266544T PT2266544T PT100123942T PT10012394T PT2266544T PT 2266544 T PT2266544 T PT 2266544T PT 100123942 T PT100123942 T PT 100123942T PT 10012394 T PT10012394 T PT 10012394T PT 2266544 T PT2266544 T PT 2266544T
- Authority
- PT
- Portugal
- Prior art keywords
- cells
- therapeutic substances
- introducing therapeutic
- introducing
- substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Radiology & Medical Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005039579.1A DE102005039579B4 (de) | 2005-08-19 | 2005-08-19 | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
US71140705P | 2005-08-26 | 2005-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2266544T true PT2266544T (pt) | 2017-08-16 |
Family
ID=39676367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT100123942T PT2266544T (pt) | 2005-08-19 | 2006-08-21 | Método para introdução de substâncias terapêuticas em células |
Country Status (16)
Country | Link |
---|---|
US (3) | US20080187595A1 (pt) |
EP (2) | EP2266544B1 (pt) |
JP (1) | JP5512968B2 (pt) |
KR (2) | KR20080034925A (pt) |
CN (2) | CN101299998A (pt) |
AU (1) | AU2006281783B2 (pt) |
BR (1) | BRPI0614835A2 (pt) |
CA (1) | CA2619278C (pt) |
DE (1) | DE102005039579B4 (pt) |
DK (1) | DK2266544T3 (pt) |
ES (1) | ES2635493T3 (pt) |
IL (1) | IL189079A (pt) |
PL (1) | PL2266544T3 (pt) |
PT (1) | PT2266544T (pt) |
RU (1) | RU2480201C2 (pt) |
WO (1) | WO2007019845A2 (pt) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
US8093038B2 (en) | 2007-09-17 | 2012-01-10 | Illinois Institute Of Technology | Apparatus and method for encapsulating pancreatic cells |
DE102008003615A1 (de) * | 2008-01-09 | 2009-07-16 | Magforce Nanotechnologies Ag | Magnetische Transducer |
DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
US8236284B1 (en) | 2008-04-02 | 2012-08-07 | University Of Central Florida Research Foundation, Inc. | Multimodal, multifunctional polymer coated nanoparticles |
US20110212142A1 (en) * | 2008-11-17 | 2011-09-01 | Laila Pharmaceuticals Pvt.Ltd. | Curcuminoids and its metabolites for the application in ocular diseases |
JP5739816B2 (ja) | 2008-12-19 | 2015-06-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Tfpiインヒビターおよび使用法 |
US20110311452A1 (en) * | 2008-12-23 | 2011-12-22 | Board Of Regents Of The University Of Texas System | Inflammation targeting particles |
PL222496B1 (pl) | 2009-04-10 | 2016-08-31 | Inst Biochemii I Biofizyki Pan | Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną |
CN101885905B (zh) * | 2009-05-12 | 2013-08-21 | 无锡纳奥新材料科技有限公司 | 聚合物/无机纳米粒子复合纳米颗粒及其制备和用途 |
CN101991597B (zh) * | 2009-08-29 | 2012-07-04 | 鲁南制药集团股份有限公司 | 一种口服药物组合物在制备预防或治疗肾脏疾病药物中的用途 |
CN101991596B (zh) * | 2009-08-29 | 2012-02-01 | 鲁南制药集团股份有限公司 | 一种口服药物组合物在制备预防或治疗冠心病的药物中的用途 |
WO2011053901A2 (en) | 2009-10-30 | 2011-05-05 | Northwestern University | Magnetic nanostructures as theranostic agents |
EP2528601A1 (en) | 2010-01-26 | 2012-12-05 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Compositions and methods for prevention and treatment of pulmonary hypertension |
NZ603028A (en) | 2010-03-19 | 2014-11-28 | Baxter Healthcare Sa | Tfpi inhibitors and methods of use |
KR101668029B1 (ko) | 2010-04-16 | 2016-10-20 | 코웨이 주식회사 | 라파콜을 유효성분으로 포함하는 주름개선용 화장료 조성물 |
CA2798180A1 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
WO2011146819A2 (en) * | 2010-05-20 | 2011-11-24 | Dmd Therapies, Llc | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES |
WO2011150212A2 (en) * | 2010-05-26 | 2011-12-01 | The General Hospital Corporation | Magnetic nanoparticles |
EP2450058A1 (en) * | 2010-08-23 | 2012-05-09 | Matera Lda | Antimicrobial nanoparticle conjugates |
WO2012081038A2 (en) * | 2010-12-17 | 2012-06-21 | Godavari Biorefineries Limited | Anticancer compounds and targeting cancer with the same |
JP2014515007A (ja) | 2011-02-25 | 2014-06-26 | サウス ダコタ ステート ユニバーシティー | 局所送達のためのタンパク質ナノ担体 |
ES2807209T3 (es) * | 2011-08-10 | 2021-02-22 | Magforce Ag | Método para fabricar nanopartículas magnéticas aglomerantes recubiertas con alcoxisilano |
US20130178691A1 (en) * | 2012-01-11 | 2013-07-11 | Petr Saha | Electrically lossy magnetic liquid composition for controlled tissue heating |
US20130195752A1 (en) | 2012-02-01 | 2013-08-01 | Regents Of The University Of Minnesota | Functionalized nanoparticles and methods of use thereof |
KR102263685B1 (ko) | 2012-03-21 | 2021-06-11 | 다케다 야쿠힌 고교 가부시키가이샤 | Tfpi 저해제 및 사용 방법 |
JP6378170B2 (ja) | 2012-04-12 | 2018-08-22 | イェール ユニバーシティーYale University | 異なる医薬品の制御送達のためのビヒクル |
CA2872652A1 (en) * | 2012-05-07 | 2013-11-14 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
TWI583395B (zh) * | 2012-05-22 | 2017-05-21 | 長庚大學 | A mixture of cells for promoting cell uptake and a preparation method thereof |
DE102012213839B4 (de) * | 2012-08-03 | 2017-06-14 | Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. | Verfahren zur kontrollierten Bewegung von Objekten in flüssigen Medien |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US20150272922A1 (en) * | 2012-11-09 | 2015-10-01 | Bioniche Life Sciences Inc. | Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof |
CN103239430B (zh) * | 2013-05-08 | 2015-01-07 | 首都医科大学 | 拉帕醇在制备预防和/或治疗恶性胶质瘤的产品中的应用 |
RU2554219C2 (ru) * | 2013-05-17 | 2015-06-27 | Общество с ограниченной ответственностью "ТехноМикрон" | Способ лазерной термотерапии кожи и ее придатков, фармацевтическая композиция для него и их применение |
JP6387400B2 (ja) | 2013-05-30 | 2018-09-05 | ナノビオティックスNanobiotix | 医薬組成物、その製造および使用 |
CN103820492A (zh) * | 2013-10-29 | 2014-05-28 | 王深明 | 功能化纳米儿茶素的基因导入材料及其制备方法 |
KR102460800B1 (ko) | 2013-11-01 | 2022-10-31 | 예일 유니버시티 | 면역요법용 모듈러 입자 |
RU2548722C1 (ru) * | 2013-12-06 | 2015-04-20 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола |
US9381171B2 (en) | 2013-12-19 | 2016-07-05 | Samsung Electronics Co., Ltd. | Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition |
US9320749B2 (en) | 2014-01-06 | 2016-04-26 | University Of Wyoming | Nanoparticle delivery system for targeted anti-obesity treatment |
CN103877029B (zh) * | 2014-03-10 | 2015-10-21 | 同济大学 | 一种磁性载5-氟尿嘧啶聚乳酸羟基乙酸共聚物材料的制备方法 |
EP2921179A1 (en) * | 2014-03-17 | 2015-09-23 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Micellar nanoparticles containing antitumoral glycosides |
WO2015148971A2 (en) * | 2014-03-27 | 2015-10-01 | Research Foundation Of The City University Of New York | Method for detecting or treating triple negative breast cancer |
US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
PT3223796T (pt) | 2014-11-25 | 2021-09-28 | Curadigm Sas | Composições farmacêuticas, preparação e suas utilizações |
HUE062561T2 (hu) * | 2014-11-25 | 2023-11-28 | Curadigm Sas | Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai |
NZ769187A (en) | 2014-11-25 | 2023-07-28 | Curadigm Sas | Pharmaceutical composition, preparation and uses thereof |
US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
US9795624B2 (en) | 2015-05-04 | 2017-10-24 | Research Foundation Of The City University Of New York | Cationic polymers as co-drugs for chemotherapeutic agents |
WO2016189125A1 (en) | 2015-05-28 | 2016-12-01 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
CN107007595B (zh) * | 2015-12-01 | 2019-01-25 | 哈尔滨商业大学 | 水鬼蕉新碱a在制备抗炎药物中的应用 |
CN106074562B (zh) * | 2016-06-16 | 2018-10-09 | 武汉大学 | 桦木酸作为机体镉清除剂的应用 |
US11260132B2 (en) | 2017-03-16 | 2022-03-01 | Children's Medical Center Corporation | Engineered liposomes as cancer-targeted therapeutics |
KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
KR101970808B1 (ko) * | 2017-07-21 | 2019-04-22 | 스노우화이트팩토리(주) | 화합물이 직접 결합된 마그헤마이트 나노입자 및 이의 제조방법 |
KR102004333B1 (ko) * | 2017-12-13 | 2019-07-26 | 단국대학교 천안캠퍼스 산학협력단 | 내부에 공동을 가지는 구형 나노입자 및 그 용도 |
PL424773A1 (pl) * | 2018-03-06 | 2019-09-09 | Nanovelos Spółka Akcyjna | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
RU2665922C1 (ru) * | 2018-04-24 | 2018-09-05 | Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Казанский научный центр Российской академии наук" | Фосфониевые соли на основе бетулиновой кислоты, обладающие цитотоксической активностью в отношении аденокарциномы предстательной железы |
SG11202010430QA (en) * | 2018-04-24 | 2020-11-27 | Amgen Inc | Method for making injectable pharmaceutical compositions |
JP7402827B2 (ja) * | 2018-06-11 | 2023-12-21 | エピセントアールエックス,インコーポレイテッド | 医薬注入デバイス、系および方法 |
US11464858B2 (en) | 2018-06-23 | 2022-10-11 | University Of Wyoming | Magnetic nanoparticle delivery system for pain therapy |
WO2020194034A1 (en) | 2019-03-27 | 2020-10-01 | Universidad De Chile | Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it |
CN110024721B (zh) * | 2019-04-29 | 2021-09-21 | 中国水产科学研究院北戴河中心实验站 | 一种诱导鲆鲽鱼类卵巢生殖细胞凋亡的方法 |
CN110201216B (zh) * | 2019-07-24 | 2021-10-08 | 中国人民解放军陆军军医大学第二附属医院 | 一种用于贯穿伤快速止血材料及其制备方法 |
CA3160054A1 (en) | 2019-12-11 | 2021-06-17 | Bryan ORONSKY | Medication infusion devices, systems, and methods |
MX2019015508A (es) | 2019-12-18 | 2021-06-21 | Univ Guadalajara | Nanopartículas para el tratamiento del cáncer. |
CN110935018A (zh) * | 2019-12-23 | 2020-03-31 | 新乡医学院 | 治疗乳腺癌的药物或组合物 |
CN111494382A (zh) * | 2020-05-28 | 2020-08-07 | 吉林大学 | 氯化两面针碱的新应用 |
CN112410295B (zh) * | 2020-11-20 | 2023-07-28 | 华东理工大学 | 一种控制细胞间相互作用的细胞表面工程方法及其应用 |
CN112274525B (zh) * | 2020-12-04 | 2022-04-08 | 遵义医科大学 | 一种化疗药物组合物及其应用 |
CN113274396A (zh) * | 2021-06-09 | 2021-08-20 | 重庆医科大学 | 植物固醇在制备预防或治疗肺癌药物中的应用 |
CN113711960A (zh) * | 2021-09-30 | 2021-11-30 | 北部湾大学 | 一种降低海水珍珠贝异种移植免疫排斥的方法 |
CN116763756A (zh) * | 2022-10-11 | 2023-09-19 | 中国科学院化学研究所 | 一种脂质纳米颗粒及其制备方法和应用 |
CN116271028A (zh) * | 2023-03-14 | 2023-06-23 | 浙江省人民医院 | 一种免疫调节性斑蝥素磁响应纳米药物及制备方法 |
CN116143705B (zh) * | 2023-04-11 | 2023-06-30 | 齐泽(云南)生物科技有限公司 | 一种药用化合物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5411730A (en) * | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
DE19515820A1 (de) | 1995-04-29 | 1996-10-31 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung schwach agglomerierter nanoskaliger Teilchen |
US6147205A (en) * | 1995-12-15 | 2000-11-14 | Affymetrix, Inc. | Photocleavable protecting groups and methods for their use |
DE19614136A1 (de) * | 1996-04-10 | 1997-10-16 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug |
DE19714949A1 (de) | 1997-04-10 | 1998-10-15 | Inst Neue Mat Gemein Gmbh | Verfahren zum Versehen einer metallischen Oberfläche mit einer glasartigen Schicht |
DE19726282A1 (de) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
WO2000006244A2 (en) * | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
DE19912798C1 (de) * | 1999-03-10 | 2000-02-17 | Andreas Jordan | Verfahren zur Kultivierung von Krebszellen aus Humangewebe und Vorrichtung zur Aufbereitung von Gewebeproben |
DE19912502A1 (de) * | 1999-03-19 | 2000-09-21 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung |
DE19940220B4 (de) * | 1999-08-19 | 2007-05-03 | Magforce Nanotechnologies Ag | Medizinisches Präparat zur Behandlung von Arthrose, Arthritis und anderen rheumatischen Gelenkerkrankungen |
US6530944B2 (en) * | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
DE10020376A1 (de) * | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamische Marker |
DE10059151C2 (de) | 2000-11-29 | 2003-10-16 | Christoph Alexiou | Magnetische Partikel zur zielgerichteten regionalen Therapie und Verwendung derselben |
CN1646549A (zh) * | 2002-02-04 | 2005-07-27 | 财团法人理工学振兴会 | 结合铁氧体的有机物及其制备方法 |
JP2004305055A (ja) | 2003-04-04 | 2004-11-04 | Hitachi Maxell Ltd | 磁性複合粒子およびその製造方法 |
WO2005044224A2 (en) * | 2003-05-02 | 2005-05-19 | Case Western Reserve University | Drug delivery system based on polymer nanoshells |
US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
PT1853250E (pt) * | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
-
2005
- 2005-08-19 DE DE102005039579.1A patent/DE102005039579B4/de not_active Expired - Fee Related
-
2006
- 2006-08-21 EP EP10012394.2A patent/EP2266544B1/de active Active
- 2006-08-21 CN CNA2006800299591A patent/CN101299998A/zh active Pending
- 2006-08-21 JP JP2008526372A patent/JP5512968B2/ja not_active Expired - Fee Related
- 2006-08-21 KR KR1020087003450A patent/KR20080034925A/ko not_active Application Discontinuation
- 2006-08-21 PL PL10012394T patent/PL2266544T3/pl unknown
- 2006-08-21 CN CN2012101780162A patent/CN102716068A/zh active Pending
- 2006-08-21 US US12/064,236 patent/US20080187595A1/en not_active Abandoned
- 2006-08-21 DK DK10012394.2T patent/DK2266544T3/en active
- 2006-08-21 BR BRPI0614835-2A patent/BRPI0614835A2/pt not_active IP Right Cessation
- 2006-08-21 AU AU2006281783A patent/AU2006281783B2/en not_active Ceased
- 2006-08-21 WO PCT/DE2006/001453 patent/WO2007019845A2/de active Application Filing
- 2006-08-21 ES ES10012394.2T patent/ES2635493T3/es active Active
- 2006-08-21 KR KR1020117017717A patent/KR20110094222A/ko not_active Application Discontinuation
- 2006-08-21 EP EP06775877A patent/EP1917004A2/de not_active Withdrawn
- 2006-08-21 RU RU2008110324/15A patent/RU2480201C2/ru not_active Application Discontinuation
- 2006-08-21 CA CA2619278A patent/CA2619278C/en active Active
- 2006-08-21 PT PT100123942T patent/PT2266544T/pt unknown
-
2008
- 2008-01-28 IL IL189079A patent/IL189079A/en active IP Right Grant
-
2012
- 2012-05-11 US US13/470,166 patent/US20120225128A1/en not_active Abandoned
-
2015
- 2015-09-09 US US14/849,053 patent/US9827312B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2266544A2 (de) | 2010-12-29 |
US20160067338A1 (en) | 2016-03-10 |
CN101299998A (zh) | 2008-11-05 |
DE102005039579B4 (de) | 2022-06-30 |
CA2619278A1 (en) | 2007-02-02 |
US9827312B2 (en) | 2017-11-28 |
CA2619278C (en) | 2013-08-06 |
AU2006281783B2 (en) | 2011-07-14 |
IL189079A0 (en) | 2008-08-07 |
BRPI0614835A2 (pt) | 2012-12-04 |
EP2266544A3 (de) | 2012-08-08 |
EP2266544B1 (de) | 2017-06-28 |
WO2007019845A2 (de) | 2007-02-22 |
US20080187595A1 (en) | 2008-08-07 |
AU2006281783A1 (en) | 2007-02-22 |
US20120225128A1 (en) | 2012-09-06 |
JP5512968B2 (ja) | 2014-06-04 |
JP2009504688A (ja) | 2009-02-05 |
IL189079A (en) | 2015-08-31 |
EP1917004A2 (de) | 2008-05-07 |
PL2266544T3 (pl) | 2017-10-31 |
WO2007019845A8 (de) | 2008-06-19 |
RU2008110324A (ru) | 2009-09-27 |
DK2266544T3 (en) | 2017-10-02 |
RU2480201C2 (ru) | 2013-04-27 |
CN102716068A (zh) | 2012-10-10 |
KR20080034925A (ko) | 2008-04-22 |
WO2007019845B1 (de) | 2007-06-14 |
KR20110094222A (ko) | 2011-08-22 |
DE102005039579A1 (de) | 2007-02-22 |
WO2007019845A3 (de) | 2007-04-19 |
ES2635493T3 (es) | 2017-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2266544T (pt) | Método para introdução de substâncias terapêuticas em células | |
GB0526291D0 (en) | Therapeutic method | |
GB2411178A8 (en) | Apparatus for culturing cells | |
LT2573166T (lt) | T ląstelių paruošimo būdas ląstelių terapijai | |
EP1897008A4 (en) | PROCESS FOR CREATING STANDARD CELLS DESIGNED ON THE BASIS OF PRIMITIVES | |
EP1813677A4 (en) | PROCESS FOR MAKING BASIC SUBSTANCE | |
IL184262A (en) | A method for culturing cells in culture | |
EP2022843A4 (en) | APPARATUS FOR SELECTING CELLS | |
EP2169070A4 (en) | METHOD FOR INTRODUCING A FOREIGN SUBSTANCE INTO A CELL WALL CELL | |
IL185207A0 (en) | Method and apparatus for separating cells | |
GB0522303D0 (en) | Culture method | |
EP1906975A4 (en) | METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE | |
GB0904267D0 (en) | Method for cell analysis | |
EP1753867A4 (en) | FERMENTATION PROCESSES | |
EP1721871A4 (en) | PROCESS FOR GENERATING BIOGAS | |
ZA200606178B (en) | Water-softening method | |
EP1776182A4 (en) | APPARATUS FOR ENCAPSULATING CELLS | |
EP1725652A4 (en) | CULTURE PROCESSES OF CRYPTOSPORIDIUM | |
HU0501174D0 (en) | Apparatus for introducing organwind | |
GB0513631D0 (en) | Electrode and method for making electrode | |
GB0607153D0 (en) | Therapeutic Method | |
GB0413136D0 (en) | Water-softening method | |
TWI315261B (en) | Method for transferring-printing | |
EP1871871A4 (en) | PROCESS FOR ACTIVATION OF T4 LYMPHOCYTES | |
IL184372A0 (en) | Method for delivering interferon-?? |